IO Interactive Welcomes Ulas Karademir as New Chief Technology Officer
15.5.2024 16:00:00 EEST | Business Wire | Press release
IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Ulas Karademir will be joining IOI as its new Chief Technology Officer, reporting to IOI’s CEO, Hakan Abrak. This strategic appointment to IOI’s leadership confirms the studio’s commitment to delivering groundbreaking experiences to its players. In his new role, Ulas will oversee IOI’s technical operations, the continuous development of Glacier, IOI’s proprietary in-house game engine, as well as working closely with the production team on the studio’s current projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513208152/en/
Ulas Karademir © IO Interactive
Ulas is a familiar face at IO Interactive, having worked there for more than seven years between 2007 and 2014. With over 20 years of experience in engineering and leadership, Ulas held roles at Unity, including over 7 years as Vice President of Core Engineering, Graphics, Operations, and Productions, and most recently at RealityOS as General Manager and CPO.
"From the moment I stepped away from the studio, I felt deep down that I would find my way back, and now, that moment has arrived. I eagerly anticipate contributing to incredible titles such as Hitman, Glacier, Project 007 and Project Fantasy and the awesome management team Hakan put together. IOI has always been known for innovation, great gameplay, and immersive worlds, and I am determined to elevate our standards even further," shared Ulas Karademir.
“Ulas is a tremendous addition to our team, bringing with him invaluable experience, knowledge, and leadership. Since he left IOI, Ulas has had an incredible track record in the different companies he worked in, and we are very excited to welcome him once more. As IOI is growing and we are looking to bring amazing IPs to our players, Ulas will be at the forefront of our innovative endeavors,” said Hakan Abrak, CEO of IO Interactive.
Ulas Karademir’s arrival is the latest of IO Interactive's appointments among its leadership, with Veronique Lallier having joined as its Chief Development Officer last January and Olivier Perbet as its Chief Marketing Officer last year.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers
About IO INTERACTIVE
IO Interactive is an independent videogame developer and publisher with studios in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton. As the creative force behind some of the most talked-about multiplatform videogames in the last two decades, IOI is dedicated to creating unforgettable characters and experiences using their award-winning proprietary Glacier technology. IO Interactive will develop and publish the very first James Bond origin story with the working title Project 007 and is currently developing a new IP under the codename Project Fantasy. For more information, visit: https://ioi.dk.
© 2024 IO Interactive A/S. IO Interactive, IOI, HITMAN are registered trademarks of IO Interactive A/S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513208152/en/
Contact information
Global Senior Communication Manager
Yann Roskell
press@ioi.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom